Published in Gene Therapy Weekly, March 29th, 1999
J.S. Bartlett and colleagues from the University of North Carolina, developed a system for the targeted delivery of adeno-associated virus (AAV) vectors ("Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F(ab 'gamma)(2) Antibody," Nature Biotechnology, February 1999;17(2):181-186).
"Targeting is achieved via a bispecific F(ab')(2) antibody that mediates a novel interaction between the AAV vector and a specific cell surface receptor expressed on human megakaryocytes," wrote Bartlett et al. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.